Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.
Yield10 Biosciences Shares See Spike In Volume Following Circulation Of Australian Patent Doc For Co.’s ‘Transgenic land plants comprising enhanced levels of mitochondrial transporter protein’
http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do
